Table 3.
Influence of disease upon 1 year and subsequent survival in 237 patientsa
| Conventional therapy |
Cyclosporine-steroids |
|||||
|---|---|---|---|---|---|---|
| No. | 1 year | Nowb | No. | 1 Year | Nowc | |
| Biliary atresia | 51 | 14 (27%) | 7 (14%) | 11 | 6 (54.5%) | 6 (54.5%) |
| Nonalcoholic cirrhosis | 46 | 16 (34.8%) | 10 (21.7%) | 16 | 9 (56.3%) | 8 (50%) |
| Primary liver malignancy | 18 | 5 (27.8%) | 1 (5.6%) | 9 | 6 (66.7%) | 4 (44.4%) |
| α-1-antitrypsin deficiency | 11 | 6 (54.5%) | 5 (45.5%) | 6 | 3 (50%) | 3 (50%) |
| Other inborn errorsd | 4 | 2 (50%) | 1 (25%) | 4 | 4 (100%) | 4 (100%) |
| Alcoholic cirrhosis | 15 | 4 (26.7%) | 3 (20%) | 0 | — | — |
| Primary biliary cirrhosis | 6 | 1 (16.7%) | 1 (16.7%) | 6 | 5 (83.3%) | 5 (83.3%) |
| Sclerosing cholangitis | 7 | 2 (28.6%) | 0 (0%) | 3 | 2 (66.7%) | 1 (33.3%) |
| Secondary biliary cirrhosis | 4 | 3 (75%) | 2 (50%) | 5 | 1 (20%) | 1 (20%) |
| Budd-Chiari syndrome | 1 | 1 (100%) | 1 (100%) | 3 | 3 (100%) | 1 (33.3%) |
| Miscellaneouse | 7 | 2 (28.6%) | 1 (14.3%) | 4 | 3 (75%) | 3 (75%) |
a
The same case material was analyzed in detail elsewhere (2) but with shorter follow-ups.
b
Follow-ups 3½ to 13½ years.
c
Follow-ups 1 to 3¼ years.
d
Wilson’s disease (3 examples), tyrosinemia (2 examples), glycogen storage disease (2 examples), and sea blue histiocyte syndrome (1 sample).
e
Neonatal hepatitis (3 examples), congenital hepatic fibrosis (2 examples), Byler’s disease (2 examples), adenomatosis, hemachromatosis, protoporphyria, and acute hepatitis B (1 example each).